Most Recent Stories
More NewsDelivers double digit net revenue growth in Canada Cannabis contributing to a narrowing net loss; financial strength of $371M in cash and cash equivalents with a net cash position of $146M at December...
Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX:WEED, NASDAQ:CGC) will release its financial results for the third quarter fiscal year 2026 ended December 31, 2025 before financial...
This news release constitutes a “designated news release” for the purposes of Canopy Growth’s prospectus supplement dated August 29, 2025 to its short form base shelf prospectus dated June 5, 2024...
Federal rescheduling efforts, coupled with improved corporate balance sheets, may finally unlock long-awaited profitability for cannabis-sector leaders.
Canopy Growth soars on reports the White House is considering reclassifying cannabis as a “Schedule III” drug. Here’s why CGC shares currently look attractive as a long-term holding.
Down almost 70% from all-time highs, Curaleaf stock offers significant upside potential given its widening free cash flow margins.
This news release constitutes a “designated news release” for the purposes of Canopy Growth’s prospectus supplement dated August 29, 2025 to its short form base shelf prospectus dated June 5, 2024...
New high-performance AIO vapes and infused pre-roll variety packs further Claybourne’s continued growth as one of the fastest-rising brands 1 in Canada’s adult-use market
Expanded formats strengthen Canopy Growth’s medical offering as patient demand rises
Canopy Growth’s latest results showcased stronger execution and renewed momentum across key markets. Is CGC stock finally turning the corner this November?